Morgan Stanley’s IceCure Medical ICCM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$5.12K Buy
567
+400
+240% +$7.31K ﹤0.01% 7129
2025
Q4
$3.05K Buy
167
+90
+117% +$2.02K ﹤0.01% 7164
2025
Q3
$2.33K Buy
77
+17
+28% +$507 ﹤0.01% 7274
2025
Q2
$1.79K Buy
60
+37
+161% +$1.19K ﹤0.01% 7247
2025
Q1
$823 Sell
23
-179
-89% -$7.01K ﹤0.01% 7310
2024
Q4
$6.68K Hold
202
﹤0.01% 6928
2024
Q3
$3.7K Hold
202
﹤0.01% 6992
2024
Q2
$4.49K Hold
202
﹤0.01% 6875
2024
Q1
$7.28K Sell
202
-203
-50% -$7.93K ﹤0.01% 6796
2023
Q4
$13K Buy
+405
New +$10.7K ﹤0.01% 6779
2022
Q1
Sell
-33
Closed -$3K 8028
2021
Q4
$3K Buy
+33
New +$5.51K ﹤0.01% 7740

Other funds holding ICCM

Morgan Stanley's ICCM Position: Q1 2026 in Review

Morgan Stanley increased its IceCure Medical (ICCM) stake by 240% in Q1 2026, buying an estimated $7.31K and bringing the position to 567 shares worth $5.12K. The position accounts for ﹤0.01% of the portfolio, ranked #7129.

Morgan Stanley first reported a position in ICCM in Q4 2021 and has held it in 11 quarters since. The position peaked at $13K in Q4 2023. 17 funds tracked by Wall St. Rank hold ICCM as of Q1 2026.

  • Morgan Stanley held 567 shares of IceCure Medical worth $5.12K as of Q1 2026.
  • Morgan Stanley bought 400 IceCure Medical shares in Q1 2026, an estimated $7.31K.
  • IceCure Medical made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #7129 holding.
  • Morgan Stanley first reported a position in IceCure Medical in Q4 2021 and has held it in 11 quarters since.
  • Morgan Stanley's IceCure Medical position peaked at $13K in Q4 2023.
  • 17 funds tracked by Wall St. Rank held IceCure Medical as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.